Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2016

01-05-2016 | Mini Review

Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

Authors: Stefania Bulotta, Marilena Celano, Giuseppe Costante, Diego Russo

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

Efficient treatment of radio refractory thyroid cancer is still a major challenge. The recent identification of genetic and epigenetic alterations present in almost all differentiated tumors has revealed novel molecular targets, which can hopefully be exploited to create new treatments for these tumors. This review looks briefly at some of the innovative strategies currently being investigated for the treatment the radioiodine-resistant thyroid cancers.
Literature
1.
L. Lamartina, C. Durante, S. Filetti, D.S. Cooper, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100, 1748–1761 (2015)CrossRefPubMed
2.
E.L. Mazzaferri, R.T. Kloos, Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86, 1447–1463 (2001)CrossRefPubMed
3.
C. Durante, G. Costante, S. Filetti, Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocr. Relat. Cancer 20, R141–R154 (2013)CrossRefPubMed
4.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)CrossRef
5.
C. Durante, T. Montesano, M. Torlontano, M. Attard, F. Monzani, S. Tumino, G. Costante, D. Meringolo, R. Bruno, F. Trulli, M. Massa, A. Maniglia, R. D’Apollo, L. Giacomelli, G. Ronga, S. Filetti, PTC Study Group, Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J. Clin. Endocrinol. Metab. 98, 636–642 (2013)CrossRefPubMed
6.
G. Dai, O. Levy, N. Carrasco, Cloning and characterization of the thyroid iodide transporter. Nature 379, 458–460 (1996)CrossRefPubMed
7.
E. Darrouzet, S. Lindenthal, D. Marcellin, J.L. Pellequer, T. Pourcher, The sodium/iodide symporter: State of the art of its molecular characterization. Biochim. Biophys. Acta 1838, 244–253 (2014)CrossRefPubMed
8.
9.
S. Filetti, J.M. Bidart, F. Arturi, B. Caillou, D. Russo, M. Schlumberger, Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur. J. Endocrinol. 141, 443–457 (1999)CrossRefPubMed
10.
V. Lazar, J.M. Bidart, B. Caillou, C. Mahé, L. Lacroix, S. Filetti, M. Schlumberger, Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J. Clin. Endocrinol. Metab. 84, 3228–3234 (1999)PubMed
11.
F. Arturi, D. Russo, M. Schlumberger, J.A. du Villard, B. Caillou, P. Vigneri, R. Wicker, E. Chiefari, H.G. Suarez, S. Filetti, Iodide symporter gene expression in human thyroid tumors. J. Clin. Endocrinol. Metab. 83, 2493–2496 (1998)PubMed
12.
F. Arturi, D. Russo, D. Giuffrida, M. Schlumberger, S. Filetti, Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur. J. Endocrinol. 143, 623–627 (2000)CrossRefPubMed
13.
F. Arturi, D. Russo, J.M. Bidart, D. Scarpelli, M. Schlumberger, S. Filetti, Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur. J. Endocrinol. 145, 129–135 (2001)CrossRefPubMed
14.
T. Saito, T. Endo, A. Kawaguchi, M. Ikeda, R. Katoh, A. Kawaoi, A. Muramatsu, T.J. Onaya, Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. Clin. Invest. 101, 1296–1300 (1998)CrossRef
15.
O. Dohán, Z. Baloch, Z. Bánrévi, V. Livolsi, N. Carrasco, Rapid communication: predominant intracellular overexpression of the Na(+)/I(−) symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 86, 2697–2700 (2001)PubMed
16.
I.L. Wapnir, M. van de Rijn, K. Nowels, P.S. Amenta, K. Walton, K. Montgomery, R.S. Greco, O. Dohán, N. Carrasco, Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J. Clin. Endocrinol. Metab. 8, 1880–1888 (2003)CrossRef
17.
V.E. Smith, M.L. Read, A.S. Turnell, R.J. Watkins, J.C. Watkinson, G.D. Lewy, J.C. Fong, S.R. James, M.C. Eggo, K. Boelaert, J.A. Franklyn, C.J. McCabe, A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J. Cell Sci. 122, 3393–3402 (2009)CrossRefPubMedPubMedCentral
18.
C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, E. Tosi, A. Cavaliere, A. Gulino, S. Filetti, D. Russo, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92, 2840–2843 (2007)CrossRefPubMed
19.
J.A. Fagin, Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. J. Clin. Endocrinol. Metab. 89, 4264–4266 (2004)CrossRefPubMed
20.
G. Riesco-Eizaguirre, P. Gutiérrez-Martínez, M.A. García-Cabezas, M. Nistal, P. Santisteban, The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer 13, 257–269 (2006)CrossRefPubMed
21.
E. Fröhlich, R. Wahl, The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. Cancer Treat. Rev. 40, 665–674 (2014)CrossRefPubMed
22.
M. Luster, T. Weber, F.A. Verburg, Differentiated thyroid cancer-personalized therapies to prevent overtreatment. Nat. Rev. Endocrinol. 10, 563–574 (2014)CrossRefPubMed
23.
C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006)CrossRefPubMed
24.
25.
Cancer Genome Atlas Research Network, Integrated genomic characterization of papillary thyroid cancer. Cell 159, 676–690 (2014)CrossRef
26.
27.
28.
C. Spitzweg, K.C. Bible, L.C. Hofbauer, J.C. Morris, Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2, 830–842 (2014)CrossRefPubMed
29.
D. Russo, G. Damante, E. Puxeddu, C. Durante, S. Filetti, Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol. 46, R73–R81 (2011)CrossRefPubMed
30.
M.D. Castellone, F. Carlomagno, G. Salvatore, M. Santoro, Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract. Clin. Endocrinol. Metab. 22, 1023–1038 (2008)CrossRef
31.
M. Saiselet, S. Floor, M. Tarabichi, G. Dom, A. Hébrant, W.C. van Staveren, C. Maenhaut, Thyroid cancer cell lines: an overview. Front. Endocrinol. 3, 133 (2012)CrossRef
32.
33.
M.J. Schlumberger, R. Elisei, L. Bastholt, L.J. Wirth, R.G. Martins, L.D. Locati, B. Jarzab, F. Pacini, C. Daumerie, J.P. Droz, M.J. Eschenberg, Y.N. Sun, T. Juan, D.E. Stepan, S.I. Sherman, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol. 27, 3794–3801 (2009)CrossRefPubMed
34.
V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, K. Ransone, S.J. Mandel, K.T. Flaherty, L.A. Loevner, P.J. O’Dwyer, M.S. Brose, Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26, 4714–4719 (2008)CrossRefPubMedPubMedCentral
35.
R.T. Kloos, M.D. Ringel, M.V. Knopp, N.C. Hall, M. King, R. Stevens, J. Liang, P.E. Wakely Jr, V.V. Vasko, M. Saji, J. Rittenberry, L. Wei, D. Arbogast, M. Collamore, J.J. Wright, M. Grever, M.H. Shah, Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27, 1675–1684 (2009)CrossRefPubMedPubMedCentral
36.
H. Hoftijzer, K.A. Heemstra, H. Morreau, M.P. Stokkel, E.P. Corssmit, H. Gelderblom, K. Weijers, A.M. Pereira, M. Huijberts, E. Kapiteijn, J.A. Romijn, J.W. Smit, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161, 923–931 (2009)CrossRefPubMed
37.
M. Ahmed, Y. Barbachano, A. Riddel, J. Hickey, K.L. Newbold, A. Viros, K.J. Harrington, R. Marais, C.M. Nutting, Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur. J. Endocrinol. 165, 315–322 (2011)CrossRefPubMed
38.
S.M. Ferrari, U. Politti, R. Spisni, G. Materazzi, E. Baldini, S. Ulisse, P. Miccoli, A. Antonelli, P. Fallahi, Sorafenib in the treatment of thyroid cancer. Expert Rev. Anticancer Ther. 15, 863–874 (2015)CrossRefPubMed
39.
M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Peña, I. Molnár, M.J. Schlumberger, DECISION investigators, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014)CrossRefPubMedPubMedCentral
40.
M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015)CrossRefPubMed
41.
42.
S. Leboulleux, L. Bastholt, T. Krause, C. de la Fouchardiere, J. Tennvall, A. Awada, J.M. Gómez, F. Bonichon, L. Leenhardt, C. Soufflet, M. Licour, M.J. Schlumberger, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 13, 897–905 (2012)CrossRefPubMed
43.
P. Fallahi, F. Di Bari, S.M. Ferrari, R. Spisni, G. Materazzi, P. Miccoli, S. Benvenga, A. Antonelli, Selective use of vandetanib in the treatment of thyroid cancer. Drug Des. Devel. Ther. 9, 3459–3470 (2015)PubMedPubMedCentral
44.
D.G. Hardie, J.W. Scott, D.A. Pan, E.R. Hudson, Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546, 113–120 (2003)CrossRefPubMed
45.
G. Chen, S. Xu, K. Renko, M. Derwahl, Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 97, E510–E520 (2012)CrossRefPubMed
46.
H.J. Choi, T.Y. Kim, N. Chung, J.H. Yim, W.G. Kim, J.A. Kim, W.B. Kim, Y.K. Shong, The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J. Endocrinol. 211, 79–85 (2011)CrossRefPubMed
47.
R.L. Plews, A. Mohd Yusof, C. Wang, M. Saji, X. Zhang, C.S. Chen, M.D. Ringel, J.E. Phay, A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J. Clin. Endocrinol. Metab 100, E748–E756 (2015)CrossRefPubMed
48.
T. Kogai, T. Endo, T. Saito, A. Miyazaki, A. Kawaguchi, T. Onaya, Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138, 2227–2232 (1997)CrossRefPubMed
49.
F. Trapasso, R. Iuliano, E. Chiefari, F. Arturi, A. Stella, S. Filetti, A. Fusco, D. Russo, Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur. J. Endocrinol. 140, 447–451 (1999)CrossRefPubMed
50.
T. Kogai, J.M. Hershman, K. Motomura, T. Endo, T. Onaya, G.A. Brent, Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells. Endocrinology 142, 3369–3379 (2001)CrossRefPubMed
51.
D. Liu, S. Hu, P. Hou, D. Jiang, S. Condouris, M. Xing, Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 13, 1341–1349 (2007)CrossRefPubMed
52.
T. Kogai, S. Sajid-Crockett, L.S. Newmarch, Y.Y. Liu, G.A. Brent, Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J. Endocrinol. 199, 243–252 (2008)CrossRefPubMed
53.
D. Chakravarty, E. Santos, M. Ryder, J.A. Knauf, X.H. Liao, B.L. West, G. Bollag, R. Kolesnick, T.H. Thin, N. Rosen, P. Zanzonico, S.M. Larson, S. Refetoff, R. Ghossein, J.A. Fagin, Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700–4711 (2011)CrossRefPubMedPubMedCentral
54.
T. Kogai, G.A. Brent, The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol. Ther. 135, 355–370 (2012)CrossRefPubMedPubMedCentral
55.
M. Tuncel, D. Aydin, E. Yaman, U.H. Tazebay, D. Güç, A.L. Doğan, B. Taşbasan, O. Uğur, The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother. Radiopharm. 22, 443–449 (2007)CrossRefPubMed
56.
P. Hou, E. Bojdani, M. Xing, Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J. Clin. Endocrinol. Metab. 95, 820–828 (2010)CrossRefPubMedPubMedCentral
57.
C. Puppin, N. Passon, J.M. Hershman, S. Filetti, S. Bulotta, M. Celano, D. Russo, G. Damante, Cooperative effects of SAHA and VPA on NIS gene expression and proliferation of thyroid cancer cells. J. Mol. Endocrinol. 48, 217–227 (2012)CrossRef
58.
C. Schmutzler, R. Winzer, J. Meissner-Weigl, J. Köhrle, Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem. Biophys. Res. Commun. 240, 832–838 (1997)CrossRefPubMed
59.
V. Bolós, J. Grego-Bessa, J.L. de la Pompa, Notch signaling in development and cancer. Endocr. Rev. 28, 339–363 (2007)CrossRefPubMed
60.
E. Ferretti, E. Tosi, A. Po, A. Scipioni, R. Morisi, M.S. Espinola, D. Russo, C. Durante, M. Schlumberger, I. Screpanti, S. Filetti, A. Gulino, Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J. Clin. Endocrinol. Metab. 93, 4080–4087 (2008)CrossRefPubMed
61.
V.E. Smith, N. Sharma, R.J. Watkins, M.L. Read, G.A. Ryan, P.P. Kwan, A. Martin, J.C. Watkinson, K. Boelaert, J.A. Franklyn, C.J. McCabe, Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J. Clin. Endocrinol. Metab. 98, 2876–2886 (2013)CrossRefPubMedPubMedCentral
62.
G.A. Brent, T. Kogai, Cancer: novel target to enhance radioiodine uptake in thyroid cancer. Nat. Rev. Endocrinol. 9, 508–509 (2013)CrossRefPubMed
63.
D. Simon, C. Körber, M. Krausch, J. Segering, P. Groth, R. Görges, F. Grünwald, H.W. Müller-Gärtner, C. Schmutzler, J. Köhrle, H.D. Röher, C. Reiners, Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur. J. Nucl. Med. Mol. Imaging 29, 775–782 (2002)CrossRefPubMed
64.
S.M. Coelho, R. Corbo, A. Buescu, D.P. Carvalho, M. Vaisman, Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J. Endocrinol. Invest. 27, 334–339 (2004)CrossRefPubMed
65.
D. Handkiewicz-Junak, J. Roskosz, K. Hasse-Lazar, S. Szpak-Ulczok, Z. Puch, A. Kukulska, T. Olczyk, A. Piela, E. Paliczka-Cieslik, B. Jarzab, 13-cis-Retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res. 2, 8 (2009)CrossRefPubMedPubMedCentral
66.
U. Banerji, D.R. Camidge, H.M. Verheul, R. Agarwal, D. Sarker, S.B. Kaye, I.M. Desar, J.N. Timmer-Bonte, S.G. Eckhardt, K.D. Lewis, K.H. Brown, M.V. Cantarini, C. Morris, S.M. George, P.D. Smith, C.M. van Herpen, The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res. 16, 1613–1623 (2010)CrossRefPubMed
67.
A.L. Ho, R.K. Grewal, R. Leboeuf, E.J. Sherman, D.G. Pfister, D. Deandreis, K.S. Pentlow, P.B. Zanzonico, S. Haque, S. Gavane, R.A. Ghossein, J.C. Ricarte-Filho, J.M. Domínguez, R. Shen, R.M. Tuttle, S.M. Larson, J.A. Fagin, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623–632 (2013)CrossRefPubMedPubMedCentral
68.
D. Russo, C. Durante, S. Bulotta, C. Puppin, E. Puxeddu, S. Filetti, G. Damante, Targeting histone deacetylase in thyroid cancer. Expert Opin. Ther. Targets 17, 179–193 (2013)CrossRefPubMed
69.
C.J. O’Neill, J. Oucharek, D. Learoyd, S.B. Sidhu, Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15, 146–156 (2010)CrossRefPubMedPubMedCentral
70.
P.J. Harris, K.C. Bible, Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin. Investig. Drugs 20, 1357–1375 (2011)CrossRefPubMedPubMedCentral
71.
T. Alonso-Gordoa, J.J. Díez, M. Durán, E. Grande, Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 22–38 (2015)CrossRefPubMedPubMedCentral
72.
M. Sponziello, A. Verrienti, F. Rosignolo, R.F. De Rose, V. Pecce, V. Maggisano, C. Durante, S. Bulotta, G. Damante, L. Giacomelli, C.R.T. Di Gioia, S. Filetti, D. Russo, M. Celano, PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine 50, 434–441 (2015)CrossRefPubMed
73.
H. Guan, W. Liang, Z. Xie, H. Li, J. Liu, L. Liu, L. Xiu, Y. Li, Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine 48, 566–574 (2015)CrossRefPubMed
74.
L. Li, B. Lv, B. Chen, M. Guan, Y. Sun, H. Li, B. Zhang, C. Ding, S. He, Q. Zeng, Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. Biochem. Biophys. Res. Commun. 462, 314–321 (2015)CrossRefPubMed
75.
M. Celano, M.G. Calvagno, S. Bulotta, D. Paolino, F. Arturi, D. Rotiroti, S. Filetti, M. Fresta, D. Russo, Cytotoxic effects of Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 4, 63 (2004)CrossRefPubMedPubMedCentral
76.
C. Celia, M.G. Calvagno, D. Paolino, S. Bulotta, C.A. Ventura, D. Russo, M. Fresta, Improved In vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes. J. Nanosci. Nanotechnol. 8, 2102–2113 (2008)CrossRefPubMed
77.
M. Celano, S. Schenone, D. Cosco, M. Navarra, E. Puxeddu, L. Racanicchi, C. Brullo, E. Varano, S. Alcaro, E. Ferretti, G. Botta, S. Filetti, M. Fresta, M. Botta, D. Russo, Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr. Rel. Cancer 15, 499–510 (2008)CrossRef
78.
D. Paolino, D. Cosco, L. Racanicchi, E. Trapasso, C. Celia, M. Iannone, E. Puxeddu, G. Costante, S. Filetti, D. Russo, M. Fresta, Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control. Rel. 144, 144–150 (2010)CrossRef
79.
D. Paolino, D. Cosco, M. Celano, S. Moretti, E. Puxeddu, D. Russo, M. Fresta, Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer. Nanomedicine 8, 193–201 (2013)CrossRefPubMed
80.
Paolino, D., Cosco, D., Russo, D., Fresta, M.: Thyrodosomes® “TSH-conjugated nanocarrier for the treatment of thyroid cancer”. Patent No WO2012/073125, 2012
81.
D. Paolino, D. Cosco, M. Gaspari, M. Celano, J. Wolfram, P. Voce, E. Puxeddu, S. Filetti, C. Celia, M. Ferrari, D. Russo, M. Fresta, Targeting the thyroid gland with thyroid stimulating hormone (TSH)-nanoliposomes. Biomaterials 35, 7101–7109 (2014)CrossRefPubMed
82.
A. Aiello, G. Pandini, F. Frasca, E. Conte, A. Murabito, A. Sacco, M. Genua, R. Vigneri, A. Belfiore, Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147, 4463–4475 (2006)CrossRefPubMed
83.
M. D’Agostino, M. Sponziello, C. Puppin, M. Celano, V. Maggisano, F. Baldan, M. Biffoni, S. Bulotta, C. Durante, S. Filetti, G. Damante, D. Russo, Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J. Mol. Endocrinol. 52, 121–131 (2014)CrossRefPubMed
84.
E.N. Klein Hesselink, D. Steenvoorden, E. Kapiteijn, E.P. Corssmit, A.N. van der Horst-Schrivers, J.D. Lefrandt, T.P. Links, O.M. Dekkers, Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur. J. Endocrinol. 172, R215–R225 (2015)CrossRefPubMed
Metadata
Title
Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine
Authors
Stefania Bulotta
Marilena Celano
Giuseppe Costante
Diego Russo
Publication date
01-05-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0830-4

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue

Review

Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician

Original Article

Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly

Original Article

Long-term exposure to electromagnetic radiation from mobile phones and Wi-Fi devices decreases plasma prolactin, progesterone, and estrogen levels but increases uterine oxidative stress in pregnant rats and their offspring

Original Article

Vitamin D-binding protein and free vitamin D concentrations in acromegaly

Original Article

Copeptin under glucagon stimulation

Original Article

Effect of reducing iodine excess on children’s goiter prevalence in areas with high iodine in drinking water

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits